The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson, M.D., Phyllis J. Goodman, M.S., Catherine M. Tangen, Dr.P.H., M. Scott Lucia, M.D., Gary J. Miller, M.D., Ph.D., Leslie G. Ford, M.D., Michael M. Lieber, M.D., R. Duane Cespedes, M.D., James N. Atkins, M.D., Scott M. Lippman, M.D., Susie M. Carlin, B.A., Anne Ryan, R.N., Connie M. Szczepanek, R.N., B.S.N., John J. Crowley, Ph.D., and Charles A. Coltman, Jr., M.D.
Background Androgens are involved in the development of prostatecancer. Finasteride, an inhibitor of 5-reductase, inhibits theconversion of testosterone to dihydrotestosterone, the primaryandrogen in the prostate, and may reduce the risk of prostatecancer.
Methods In the Prostate Cancer Prevention Trial, we randomlyassigned 18,882 men 55 years of age or older with a normal digitalrectal examination and a prostate-specific antigen (PSA) levelof 3.0 ng per milliliter or lower to treatment with finasteride(5 mg per day) or placebo for seven years. Prostate biopsy wasrecommended if the annual PSA level, adjusted for the effectof finasteride, exceeded 4.0 ng per milliliter or if the digitalrectal examination was abnormal. It was anticipated that 60percent of participants would have prostate cancer diagnosedduring the study or would undergo biopsy at the end of the study.The primary end point was the prevalence of prostate cancerduring the seven years of the study.
Results Prostate cancer was detected in 803 of the 4368 menin the finasteride group who had data for the final analysis(18.4 percent) and 1147 of the 4692 men in the placebo groupwho had such data (24.4 percent), for a 24.8 percent reductionin prevalence over the seven-year period (95 percent confidenceinterval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleasongrade 7, 8, 9, or 10 were more common in the finasteride group(280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368men included in the final analysis) than in the placebo group(237 of 1068 tumors [22.2 percent], P<0.001 for the comparisonbetween groups; or 5.1 percent of the 4692 men included in thefinal analysis, P=0.005 for the comparison between groups).Sexual side effects were more common in finasteride-treatedmen, whereas urinary symptoms were more common in men receivingplacebo.
Conclusions Finasteride prevents or delays the appearance ofprostate cancer, but this possible benefit and a reduced riskof urinary problems must be weighed against sexual side effectsand the increased risk of high-grade prostate cancer.
Source Information
From the University of Texas Health Science Center, San Antonio (I.M.T.); the Southwest Oncology Group Statistical Center, Seattle (P.J.G., C.M.T., S.M.C., J.J.C.); the University of Colorado, Denver (M.S.L., G.J.M.); the National Cancer Institute, Bethesda, Md. (L.G.F., A.R.); the Mayo Clinic, Rochester, Minn. (M.M.L.); the Wilford Hall U.S. Air Force Medical Center, San Antonio, Tex. (R.D.C.); the Southeastern Medical Oncology Center, Goldsboro, N.C. (J.N.A.); the M.D. Anderson Cancer Center, Houston (S.M.L.); the Grand Rapids Community Clinical Oncology Program, Grand Rapids, Mich. (C.M.S.); and the Southwest Oncology Group Operations Office, San Antonio, Tex. (C.A.C.). This article was published at www.nejm.org on June 24, 2003.
Address reprint requests to the Southwest Oncology Group (SWOG-9217), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245-3217.
Prevention of Prostate Cancer with Finasteride
Rubin M. A., Kantoff P. W., Roehrborn C. G., Burke H. B., Schwartz D. T., Ross R. K., Skinner E., Cote R. J., Lee S. C., Ellis R. J., Barzell W. E., Thompson I. M. Jr., Goodman P. J., Coltman C. A. Jr.
Extract |
Full Text |
PDF
N Engl J Med 2003;
349:1569-1572, Oct 16, 2003.
Correspondence
This article has been cited by other articles:
Amory, J. K., Kalhorn, T. F., Page, S. T.
(2008). Pharmacokinetics and Pharmacodynamics of Oral Testosterone Enanthate Plus Dutasteride for 4 Weeks in Normal Men: Implications for Male Hormonal Contraception. J Androl
29: 260-271
[Abstract][Full Text]
Kristal, A. R., Arnold, K. B., Schenk, J. M., Neuhouser, M. L., Goodman, P., Penson, D. F., Thompson, I. M.
(2008). Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol
167: 925-934
[Abstract][Full Text]
Wako, K, Kawasaki, T, Yamana, K, Suzuki, K, Jiang, S, Umezu, H, Nishiyama, T, Takahashi, K, Hamakubo, T, Kodama, T, Naito, M
(2008). Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J. Clin. Pathol.
61: 448-454
[Abstract][Full Text]
Rondanina, G., Puntoni, M., Severi, G., Varricchio, C., Zunino, A., Feroce, I., Bonanni, B., Decensi, A.
(2008). Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users. JCO
26: 1537-1543
[Abstract][Full Text]
Page, S. T., Bremner, W. J., Clark, R. V., Bush, M. A., Zhi, H., Caricofe, R. B., Smith, P. M., Amory, J. K.
(2008). Nanomilled Oral Testosterone Plus Dutasteride Effectively Normalizes Serum Testosterone in Normal Men With Induced Hypogonadism. J Androl
29: 222-227
[Abstract][Full Text]
Barry, M. J.
(2008). Commentary: How Serious Is Getting a Diagnosis of Prostate Cancer?. The Oncologist
13: 306-308
[Full Text]
Gelmann, E. P.
(2008). Complexities of Prostate-Cancer Risk. NEJM
358: 961-963
[Full Text]
Helling, T. J. MD
(2008). Finasteride therapy for benign prostatic hyperplasia. CMAJ
178: 596-597
[Full Text]
Roobol, M. J., Schroder, F. H.
(2008). Re: Is a Screening Interval of Every 4 Years for Prostate Cancer Acceptable?. JNCI J Natl Cancer Inst
100: 222-222
[Full Text]
Hormones, E., Prostate Cancer Collaborative Group,
(2008). Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. JNCI J Natl Cancer Inst
100: 170-183
[Abstract][Full Text]
Carpenter, W. R., Robinson, W. R., Godley, P. A.
(2008). Getting Over Testosterone: Postulating a Fresh Start for Etiologic Studies of Prostate Cancer. JNCI J Natl Cancer Inst
100: 158-159
[Full Text]
Simoneau, A. R., Gerner, E. W., Nagle, R., Ziogas, A., Fujikawa-Brooks, S., Yerushalmi, H., Ahlering, T. E., Lieberman, R., McLaren, C. E., Anton-Culver, H., Meyskens, F. L. Jr.
(2008). The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial. Cancer Epidemiol. Biomarkers Prev.
17: 292-299
[Abstract][Full Text]
Wilt, T. J, N'Dow, J.
(2008). Benign prostatic hyperplasia. Part 2--Management. BMJ
336: 206-210
[Full Text]
Albertelli, M. A., O'Mahony, O. A., Brogley, M., Tosoian, J., Steinkamp, M., Daignault, S., Wojno, K., Robins, D. M.
(2008). Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice. Hum Mol Genet
17: 98-110
[Abstract][Full Text]
Sedjo, R. L., Byers, T., Barrera, E. Jr., Cohen, C., Fontham, E. T. H., Newman, L. A., Runowicz, C. D., Thorson, A. G., Thun, M. J., Ward, E., Wender, R. C., Eyre, H. J., for the ACS Cancer Incidence & Mortality Ends Comm,
(2007). A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. CA Cancer J Clin
57: 326-340
[Abstract][Full Text]
Platz, E. A.
(2007). Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiol. Biomarkers Prev.
16: 2175-2180
[Full Text]
Haas, G. P., Delongchamps, N. B., Jones, R. F., Chandan, V., Serio, A. M., Vickers, A. J., Jumbelic, M., Threatte, G., Korets, R., Lilja, H., de la Roza, G.
(2007). Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence. JNCI J Natl Cancer Inst
99: 1484-1489
[Abstract][Full Text]
Banach-Petrosky, W., Jessen, W. J., Ouyang, X., Gao, H., Rao, J., Quinn, J., Aronow, B. J., Abate-Shen, C.
(2007). Prolonged Exposure to Reduced Levels of Androgen Accelerates Prostate Cancer Progression in Nkx3.1; Pten Mutant Mice. Cancer Res.
67: 9089-9096
[Abstract][Full Text]
Hoque, A., Parnes, H. L., Stefanek, M. E., Heymach, J. V., Brown, P. H., Lippman, S. M.
(2007). Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res.
67: 8989-8993
[Abstract][Full Text]
Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., Kattan, M. W., Crawford, E. D., Ford, L. G., Coltman, C. A. Jr, Thompson, I. M.
(2007). Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst
99: 1375-1383
[Abstract][Full Text]
Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson, K. M., Daifotis, A. G., Gann, P. H.
(2007). Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst
99: 1366-1374
[Abstract][Full Text]
Andriole, G. L., Humphrey, P. A., Serfling, R. J., Grubb, R. L.
(2007). High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial: Fact or Artifact?. JNCI J Natl Cancer Inst
99: 1355-1356
[Full Text]
Crawford, E. D.
(2007). Is a Screening Interval of Every 4 Years for Prostate Cancer Acceptable?. JNCI J Natl Cancer Inst
99: 1279-1280
[Full Text]
Key, T. J, Appleby, P. N, Allen, N. E, Travis, R. C, Roddam, A. W, Jenab, M., Egevad, L., Tjonneland, A., Johnsen, N. F, Overvad, K., Linseisen, J., Rohrmann, S., Boeing, H., Pischon, T., Psaltopoulou, T., Trichopoulou, A., Trichopoulos, D., Palli, D., Vineis, P., Tumino, R., Berrino, F., Kiemeney, L., Bueno-de-Mesquita, H B., Quiros, J R., Gonzalez, C. A, Martinez, C., Larranaga, N., Chirlaque, M. D., Ardanaz, E., Stattin, P., Hallmans, G., Khaw, K.-T., Bingham, S., Slimani, N., Ferrari, P., Rinaldi, S., Riboli, E.
(2007). Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am. J. Clin. Nutr.
86: 672-681
[Abstract][Full Text]
Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A.S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., Kattan, M. W.
(2007). Assessing Individual Risk for Prostate Cancer. JCO
25: 3582-3588
[Abstract][Full Text]
Kauh, J., Khuri, F. R.
(2007). Can Statins Pass the Aspirin Litmus Test in Cancer?. JCO
25: 3395-3396
[Full Text]
Brown, P. H.
(2007). Chemoprevention Clinical Trials: It Is Time to Turn Success into Progress. Cancer Epidemiol. Biomarkers Prev.
16: 1531-1532
[Full Text]
de Vere White, R. W.
(2007). Finasteride for Chemoprevention of Prostate Cancer: Why Has It Not Been Embraced?. JCO
25: 2999-3000
[Full Text]
Thompson, I. M., Pauler Ankerst, D., Chi, C., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., Coltman, C. A. Jr
(2007). Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial. JCO
25: 3076-3081
[Abstract][Full Text]
Giovannucci, E.
(2007). Does Prostate-Specific Antigen Screening Influence the Results of Studies of Tomatoes, Lycopene, and Prostate Cancer Risk?. JNCI J Natl Cancer Inst
99: 1060-1062
[Full Text]
Shen, M. M., Abate-Shen, C.
(2007). Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer. Cancer Res.
67: 6535-6538
[Abstract][Full Text]
Lippman, S. M., Heymach, J. V.
(2007). The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention. Clin. Cancer Res.
13: 4035-4041
[Abstract][Full Text]
Moinpour, C. M., Darke, A. K., Donaldson, G. W., Thompson, I. M. Jr, Langley, C., Ankerst, D. P., Patrick, D. L., Ware, J. E. Jr, Ganz, P. A., Shumaker, S. A., Lippman, S. M., Coltman, C. A. Jr
(2007). Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial. JNCI J Natl Cancer Inst
99: 1025-1035
[Abstract][Full Text]
Neuhouser, M. L., Barnett, M. J., Kristal, A. R., Ambrosone, C. B., King, I., Thornquist, M., Goodman, G.
(2007). (n-6) PUFA Increase and Dairy Foods Decrease Prostate Cancer Risk in Heavy Smokers. J. Nutr.
137: 1821-1827
[Abstract][Full Text]
Araujo, A. B., Kupelian, V., Page, S. T., Handelsman, D. J., Bremner, W. J., McKinlay, J. B.
(2007). Sex Steroids and All-Cause and Cause-Specific Mortality in Men. Arch Intern Med
167: 1252-1260
[Abstract][Full Text]
Thompson, I. M., Ankerst, D. P.
(2007). Prostate-specific antigen in the early detection of prostate cancer. CMAJ
176: 1853-1858
[Abstract][Full Text]
Littman, A. J., White, E., Kristal, A. R.
(2007). Anthropometrics and Prostate Cancer Risk. Am J Epidemiol
165: 1271-1279
[Abstract][Full Text]
Freedland, S. J., Platz, E. A.
(2007). Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiol Rev
0: mxm006v1-
[Abstract][Full Text]
Neugut, A. I., Lebwohl, B., Hershman, D. L.
(2007). Cancer Chemoprevention: How Do We Know What Works?. JCO
25: 1461-1462
[Full Text]
Adolfsson, J.
(2007). Commentary: On the incidence of histological prostate cancer and the probable diagnosis of cases with tumours too small to produce symptoms or to attract attention on physical examination--the findings of Dr Arnold Rice Rich. Int J Epidemiol
0: dym053v1-3
[Full Text]
Ji, Q., Chang, L., Stanczyk, F. Z., Ookhtens, M., Sherrod, A., Stolz, A.
(2007). Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling. Cancer Res.
67: 1361-1369
[Abstract][Full Text]
Connolly, S. S, Fitzpatrick, J. M
(2007). Medical treatment of benign prostatic hyperplasia. Postgrad. Med. J.
83: 73-78
[Abstract][Full Text]
Canene-Adams, K., Lindshield, B. L., Wang, S., Jeffery, E. H., Clinton, S. K., Erdman, J. W. Jr.
(2007). Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas. Cancer Res.
67: 836-843
[Abstract][Full Text]
Rodriguez, C., Freedland, S. J., Deka, A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Thun, M. J., Calle, E. E.
(2007). Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev.
16: 63-69
[Abstract][Full Text]
Manassero, F., Erba, P., Mariani, G., Mogorovich, A., Giannarini, G., Selli, C.
(2007). Metastatic Prostate Cancer After Orchiectomy, Radiotherapy, and Testosterone Replacement in a Patient With Bilateral Seminoma. J Androl
28: 10-12
[Full Text]
Srinivasan, S., Ranga, R. S., Burikhanov, R., Han, S.-S., Chendil, D.
(2007). Par-4-Dependent Apoptosis by the Dietary Compound Withaferin A in Prostate Cancer Cells. Cancer Res.
67: 246-253
[Abstract][Full Text]
Campbell, K. L., McTiernan, A.
(2007). Exercise and Biomarkers for Cancer Prevention Studies. J. Nutr.
137: 161S-169S
[Abstract][Full Text]
Bauman, D. R., Steckelbroeck, S., Peehl, D. M., Penning, T. M.
(2006). Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and Prostate Cancer. Endocrinology
147: 5806-5816
[Abstract][Full Text]
Wilt, T. J, Thompson, I. M
(2006). Clinically localised prostate cancer. BMJ
333: 1102-1106
[Full Text]
BOSLAND, M. C
(2006). Sex Steroids and Prostate Carcinogenesis: Integrated, Multifactorial Working Hypothesis. Ann. N. Y. Acad. Sci.
1089: 168-176
[Abstract][Full Text]
Chuan, Y.-C., Pang, S.-T., Cedazo-Minguez, A., Norstedt, G., Pousette, A., Flores-Morales, A.
(2006). Androgen Induction of Prostate Cancer Cell Invasion Is Mediated by Ezrin. J. Biol. Chem.
281: 29938-29948
[Abstract][Full Text]
Gong, Z., Neuhouser, M. L., Goodman, P. J., Albanes, D., Chi, C., Hsing, A. W., Lippman, S. M., Platz, E. A., Pollak, M. N., Thompson, I. M., Kristal, A. R.
(2006). Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.. Cancer Epidemiol. Biomarkers Prev.
15: 1977-1983
[Abstract][Full Text]
Ammar, H., Malani, A. K, Gupta, C.
(2006). Benign prostatic hyperplasia: Caveat for finasteride should be discussed before prescribing. BMJ
333: 654-654
[Full Text]
Patel, A. K, Chapple, C. R
(2006). Benign prostatic hyperplasia: Authors' reply. BMJ
333: 654-654
[Full Text]
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., Coltman, C. A. Jr.
(2006). Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer.. JNCI J Natl Cancer Inst
98: 1128-1133
[Abstract][Full Text]
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., Abate-Shen, C.
(2006). Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice. Cancer Res.
66: 7929-7933
[Abstract][Full Text]
Svatek, R. S., Lee, J. J., Roehrborn, C. G., Lippman, S. M., Lotan, Y.
(2006). The cost of prostate cancer chemoprevention: a decision analysis model.. Cancer Epidemiol. Biomarkers Prev.
15: 1485-1489
[Abstract][Full Text]
Matthiesson, K. L., McLachlan, R. I.
(2006). Male hormonal contraception: concept proven, product in sight?. Hum Reprod Update
12: 463-482
[Abstract][Full Text]
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention,
(2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res.
12: 3661-3697
[Abstract][Full Text]
Roth-Cline, M. D.
(2006). Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs. Circulation
113: 2253-2259
[Full Text]
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., Coltman, C. A. Jr.
(2006). Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.. JNCI J Natl Cancer Inst
98: 529-534
[Abstract][Full Text]
Li, H.-R., Wang-Rodriguez, J., Nair, T. M., Yeakley, J. M., Kwon, Y.-S., Bibikova, M., Zheng, C., Zhou, L., Zhang, K., Downs, T., Fu, X.-D., Fan, J.-B.
(2006). Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens.. Cancer Res.
66: 4079-4088
[Abstract][Full Text]
Dolder, C. R
(2006). Dutasteride: A Dual 5-{alpha} Reductase Inhibitor for the Treatment of Symptomatic Benign Prostatic Hyperplasia. The Annals of Pharmacotherapy
40: 658-665
[Abstract][Full Text]
Lippman, S. M., Lee, J. J.
(2006). Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.. Cancer Res.
66: 2893-2903
[Abstract][Full Text]
Hayes, F.
(2006). Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men: Response to Kaplan and Crawford. Diabetes Care
29: 749-750
[Full Text]
Fontanarosa, P. B., Cole, H. M.
(2006). Theme Issue on Men's Health: Call for Papers. JAMA
295: 440-441
[Full Text]
Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., Corti, A.
(2006). Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study. Cancer Res.
66: 1234-1240
[Abstract][Full Text]
Severi, G., Morris, H. A., MacInnis, R. J., English, D. R., Tilley, W., Hopper, J. L., Boyle, P., Giles, G. G.
(2006). Circulating Steroid Hormones and the Risk of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev.
15: 86-91
[Abstract][Full Text]
Jiang, C., Lee, H.-J., Li, G.-x., Guo, J., Malewicz, B., Zhao, Y., Lee, E.-O., Lee, H.-J., Lee, J.-H., Kim, M.-S., Kim, S.-H., Lu, J.
(2006). Potent Antiandrogen and Androgen Receptor Activities of an Angelica gigas-Containing Herbal Formulation: Identification of Decursin as a Novel and Active Compound with Implications for Prevention and Treatment of Prostate Cancer. Cancer Res.
66: 453-463
[Abstract][Full Text]
Stiehm, E. R.
(2006). Disease Versus Disease: How One Disease May Ameliorate Another. Pediatrics
117: 184-191
[Abstract][Full Text]
Thompson, I. M., Tangen, C. M., Goodman, P. J., Probstfield, J. L., Moinpour, C. M., Coltman, C. A.
(2005). Erectile Dysfunction and Subsequent Cardiovascular Disease. JAMA
294: 2996-3002
[Abstract][Full Text]
Thompson, I. M., Tangen, C. M., Klein, E. A., Lippman, S. M.
(2005). Phase III Prostate Cancer Prevention Trials: Are the Costs Justified?. JCO
23: 8161-8164
[Abstract][Full Text]
Ryan, C. J., Small, E. J.
(2005). Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate. JCO
23: 8225-8231
[Abstract][Full Text]
Imamov, O., Shim, G.-J., Warner, M., Gustafsson, J.-A.
(2005). Estrogen Receptor beta in Health and Disease. Biol. Reprod.
73: 866-871
[Abstract][Full Text]
Freedland, S. J., Isaacs, W. B., Platz, E. A., Terris, M. K., Aronson, W. J., Amling, C. L., Presti, J. C. Jr, Kane, C. J.
(2005). Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study. JCO
23: 7546-7554
[Abstract][Full Text]
Talcott, J. A.
(2005). Rebalancing Ratios and Improving Impressions: Later Thoughts From the Prostate Cancer Prevention Trial Investigators. JCO
23: 7388-7390
[Full Text]
Cook, E. D, Moody-Thomas, S., Anderson, K. B, Campbell, R., Hamilton, S. J, Harrington, J. M, Lippman, S. M, Minasian, L. M, Paskett, E. D, Craine, S., Arnold, K. B, Probstfield, J. L
(2005). Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials
2: 436-442
[Abstract]
Kaufman, J. M., Vermeulen, A.
(2005). The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications. Endocr. Rev.
26: 833-876
[Abstract][Full Text]
Aus, G., Damber, J.-E., Khatami, A., Lilja, H., Stranne, J., Hugosson, J.
(2005). Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level: Results of a Prospective, Randomized, Population-Based Study. Arch Intern Med
165: 1857-1861
[Abstract][Full Text]
Thompson, I. M., Canby-Hagino, E., Lucia, M. S.
(2005). Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor. JNCI J Natl Cancer Inst
97: 1236-1237
[Full Text]
Rau, K-M, Kang, H-Y, Cha, T-L, Miller, S A, Hung, M-C
(2005). The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer
12: 511-532
[Abstract][Full Text]
Parsons, J. K., Carter, H. B., Platz, E. A., Wright, E. J., Landis, P., Metter, E. J.
(2005). Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy. Cancer Epidemiol. Biomarkers Prev.
14: 2257-2260
[Abstract][Full Text]
-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. 
Previous
